A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Fasinumab (Primary)
- Indications Pain
- Focus Therapeutic Use
- Acronyms FACT DEVICE
- Sponsors Regeneron Pharmaceuticals
- 22 Jan 2019 Planned End Date changed from 27 Jul 2020 to 31 Aug 2020.
- 22 Jan 2019 Planned primary completion date changed from 6 May 2019 to 30 Sep 2019.
- 22 Jan 2019 Planned initiation date changed from 10 Dec 2018 to 14 Jan 2019.